Literature DB >> 25932172

p53 Arg72Pro polymorphism and risk of basal cell carcinoma: a meta analysis.

Yanli Tian1, Li Li2, Rongya Yang2.   

Abstract

PURPOSE: We attempted to comprehensively assess the possible association between p53 Arg72Pro polymorphism and the risk of basal cell carcinoma (BCC).
METHODS: We performed a literature search of case-control association studies on p53 Arg72Pro polymorphism and BCC susceptibility in PubMed and EMBASE. 7 eligible studies were finally identified and their data were extracted for this meta-analysis. BCC risk was determined with the fixed effects model using a pooled odds ratio (OR).
RESULTS: Using distinct genetic models, we found that p53 Arg72Pro polymorphism was not associated with the overall risk of BCC. We observed a similar trend towards the association when performing subgroup analysis for Caucasians and Asians.
CONCLUSION: Our results suggest that presence of the common p53 Arg72Pro polymorphism may not play a role in the development of BCC. Larger studies are needed to better confirm the association.

Entities:  

Keywords:  BCC; p53; polymorphism; risk

Year:  2015        PMID: 25932172      PMCID: PMC4402819     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  33 in total

1.  Genetic polymorphism in p53 codon 72 and skin cancer in southwestern Taiwan.

Authors:  Yen-Ching Chen; Lilian Xu; Yu-Liang Leon Guo; Huey-Jen Jenny Su; Yu-Mei Hsueh; Thomas J Smith; Louise M Ryan; Meei-Shyuan Lee; Sheau-Chiou Chaor; Julia Yu-Yun Lee; David C Christiani
Journal:  J Environ Sci Health A Tox Hazard Subst Environ Eng       Date:  2003-01       Impact factor: 2.269

2.  TP53 Arg72Pro polymorphism may have little involvement in the pathogenesis of skin cancer in Caucasians.

Authors:  Yan-Feng Zou; Fang Wang; Xiao-Liang Feng
Journal:  J Invest Dermatol       Date:  2010-12-30       Impact factor: 8.551

3.  The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.

Authors:  C Venot; M Maratrat; C Dureuil; E Conseiller; L Bracco; L Debussche
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

4.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression.

Authors:  K K Walker; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

5.  Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene.

Authors:  Sophie Queille; Lionel Luron; Alain Spatz; Marie Françoise Avril; Vincent Ribrag; Pierre Duvillard; Christian Hiesse; Alain Sarasin; Jean Pierre Armand; Leela Daya-Grosjean
Journal:  Carcinogenesis       Date:  2006-10-25       Impact factor: 4.944

6.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

7.  The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer.

Authors:  Lindsay M Almquist; Margaret R Karagas; Brock C Christensen; Marleen M Welsh; Ann E Perry; Craig A Storm; Heather H Nelson
Journal:  Carcinogenesis       Date:  2010-12-01       Impact factor: 4.944

8.  p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment.

Authors:  S P Hussain; M H Hollstein; C C Harris
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

9.  Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history.

Authors:  M Murata; M Tagawa; M Kimura; H Kimura; S Watanabe; H Saisho
Journal:  Carcinogenesis       Date:  1996-02       Impact factor: 4.944

10.  Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss.

Authors:  A G Quinn; S Sikkink; J L Rees
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.